Results 11 to 20 of about 30,982 (215)
Vaccines, 2022 Emerging numbers of SARS-CoV-2 infections are currently combated with a third vaccination. Considering the different vaccination regimens used for the first two vaccine doses, we addressed whether the previous vaccination influences the immune response ...
Geßner, Reinhard +11 more
core +5 more sources
Immunogenicity and efficacy of heterologous ChAdOx1-BNT162b2 vaccination [PDF]
Nature, 2021 Following severe adverse reactions to the AstraZeneca ChAdOx1-S-nCoV-19 vaccine1,2, European health authorities recommended that patients under the age of 55?years who received one dose of ChAdOx1-S-nCoV-19 receive a second dose of the Pfizer BNT162b2 ...
Lina, Bruno +24 more
core +6 more sources
Anti-spike antibody trajectories in individuals previously immunised with BNT162b2 or ChAdOx1 following a BNT162b2 booster dose [PDF]
Wellcome Open Research, 2022 Background: The two most common SARS-CoV-2 vaccines in the UK, BNT162b2 (Pfizer-BioNTech) and ChAdOx1 nCoV-19 (Oxford-AstraZeneca), employ different immunogenic mechanisms.
Fong, Wing Lam Erica +29 more
core +6 more sources
iScience, 2022 Summary: Heterologous ChAdOx1-BNT162b2 vaccination induces a stronger immune response than BNT162b2-BNT162b2. Here, we investigated the molecular transcriptome, germline allelic variants of immunoglobulin loci, and anti-Omicron antibody levels in 46 ...
Hye Kyung Lee +8 more
doaj +2 more sources
Vaccines, 2023 This study aimed to compare adverse reactions following BNT162b2 and influenza vaccinations in healthcare workers. This study included healthcare workers who received the BNT162b2 vaccine and/or inactivated influenza vaccine, quadrivalent (IIV4), on 18 ...
A-Sol Kim +5 more
doaj +2 more sources
Acute myocarditis following administration of BNT162b2 vaccine
IDCases, 2021 The wide use of vaccines was linked with rare but serious complications in adults, causing a global concern. Here, we describe a young male patient, who presented with acute myocarditis, three days after the second dose of BNT162b2 ...
Mawahib Elhassan +9 more
core +4 more sources
Evaluation of BNT162b2 Vaccine Effectiveness in Galicia, Northwest Spain
International Journal of Environmental Research and Public Health, 2022 Investigating vaccine effectiveness (VE) in real-world conditions is crucial, especially its variation across different settings and populations. We undertook a test-negative control study in Galicia (Northwest Spain) to assess BNT162b2 effectiveness ...
Jacobo Pardo-Seco +11 more
core +3 more sources
Beyond neutralization for BNT162b2 mRNA vaccination [PDF]
Cell Host & Microbe, 2021 Mounting a robust immune response against SARS-CoV-2 requires neutralization as well as effector T cell functions. In this issue of Cell Host Microbe, Tauzin et al. characterize the humoral and T cell responses after a single dose of BNT162b2 mRNA vaccine in individuals with or without previous exposure to SARS-CoV-2.
Damani-Yokota, Payal +2 more
openaire +2 more sources
VaccinesThe SARS-CoV-2 Omicron variant and its sublineages continue to cause COVID-19-associated pediatric hospitalizations, severe disease, and death globally. BNT162b2 and CoronaVac are the main vaccines used in Chile.
Diego A. Díaz-Dinamarca +15 more
doaj +2 more sources
Comparative Safety of the BNT162b2 Messenger RNA COVID-19 Vaccine vs Other Approved Vaccines in Children Younger Than 5 Years. [PDF]
, 2022 Importance SARS-CoV-2 vaccines are authorized for use in most age groups. The safety of SARS-CoV-2 vaccines is unknown in children younger than 5 years.
von Meißner, Wolfgang C. G. +14 more
core +2 more sources